Cjc-1295 No Dac Vendor

Selecting a Verified CJC-1295 No DAC Vendor for Preclinical Research

A qualified CJC-1295 No DAC vendor must provide complete analytical transparency, lot-specific batch tracing, and verifiable chemical purity before reagents enter laboratory workflows. CJC-1295 No DAC—frequently designated in scientific literature as Modified GRF 1-29—is a synthetic 29-amino-acid peptide analog of growth hormone-releasing hormone (GHRH). When sourcing this compound, principal investigators must ensure the material is free from synthesis side-products, TFA salts, and microbial contamination.

PX1 Research operates as a primary USA-based supplier of reference-grade peptides, distributing CJC-1295 No DAC strictly for laboratory research use only. By pairing domestic manufacturing in GMP-compliant facilities with independent, third-party analytical validation, PX1 Research eliminates reagent variance and ensures high lot-to-lot consistency for quantitative biological assays.

Molecular Structure and Mechanism of Action: CJC-1295 No DAC

CJC-1295 No DAC is a truncated and modified peptide analog derived from endogenous GHRH (1-44). The native GHRH molecule is rapidly degraded in biological systems by dipeptidyl peptidase-4 (DPP-4) and endopeptidases, which cleavage the N-terminal sequence within minutes. Modified GRF 1-29 incorporates four specific amino acid substitutions—typically at positions 2, 8, 15, and 27—to enhance resistance to enzymatic degradation while preserving receptor binding affinity.

Unlike its long-acting counterpart containing the Drug Affinity Complex (DAC), CJC-1295 No DAC does not covalently bind to serum albumin. As a result, its pharmacokinetic profile reflects a brief, natural physiological pulse rather than sustained, continuous elevation of growth hormone levels. When applied in vitro or in animal models, the compound selectively binds to the GHRH receptor (GHRHR) on anterior pituitary somatotropes. This interaction stimulates adenylate cyclase, increasing intracellular cyclic adenosine monophosphate (cAMP) and initiating the pulsatile release of endogenous growth hormone (GH).

Preclinical Applications and Growth Factor Axis Studies

In preclinical laboratory settings, CJC-1295 No DAC is studied as a long-acting growth-hormone-releasing hormone analog that sustains physiological GH and downstream insulin-like growth factor 1 (IGF-1) levels for tissue repair research. Researchers utilize the peptide to investigate cellular regeneration, musculoskeletal matrix repair, metabolic signaling pathways, and nitrogen retention in animal models.

In vitro data indicate that pulsatile activation of the GHRH receptor leads to coordinated gene expression downstream of the STAT5b and MAPK signaling cascades. Preclinical studies suggest that elevating systemic IGF-1 through pulsatile GHRH stimulation enhances satellite cell proliferation, collagen deposition, and cellular protein synthesis without causing receptor desensitization. Researchers comparing various growth axis modifiers can access the broader catalog via our comprehensive all peptides directory.

Evaluating Supplier Standards: Essential COA Metrics

Selecting a reputable vendor requires systematic evaluation of the supplier's Certificate of Analysis (COA) for every product lot. A standard quality assurance protocol for research peptides should never rely on manufacturer self-testing or generic laboratory templates. Every batch must undergo dual-spectrum analysis via an independent, ISO 17025-accredited laboratory.

Primary metrics required for rigorous laboratory compliance include:

• High-Performance Liquid Chromatography (RP-HPLC): Establishes chemical purity. High-grade research reagents must exhibit single-peak chromatographic purity exceeding 98.0%.

• Electrospray Ionization Mass Spectrometry (ESI-MS): Confirms exact molecular weight and verifies the correct sequence identity against predicted theoretical mass.

• Endotoxin Quantitation (LAL Assay): Measures lipopolysaccharide contamination. Research-grade peptides should maintain endotoxin levels below 0.01 EU/mg to prevent confounding immune responses in cell cultures or animal models.

• Appearance and Solubility: Lyophilized cakes should present as uniform, white powder free of visible moisture or insoluble particulate matter upon reconstitution.

Comparative Analysis: CJC-1295 No DAC vs. DAC Variants and GH Secretagogues

In experimental design, investigators frequently contrast CJC-1295 No DAC with alternate growth axis modifiers to evaluate physiological pulsatility versus constant receptor occupancy. While CJC-1295 No DAC provides short half-life, physiological GH pulses, the DAC variant includes a maleimidopropionic acid linker that extends biological half-life to several days through albumin binding. Researchers evaluating these operational differences can explore our comparative guide on CJC-1295 vs. CJC-1295 DAC.

Furthermore, GHRH analogs like CJC-1295 No DAC are frequently evaluated alongside ghrelin receptor agonists (growth hormone secretagogue receptor, GHSR agonists). Compounds such as ipamorelin and GHRP-2 act on distinct receptor pathways. When co-administered in preclinical models, GHRH analogs and GHSR agonists exhibit synergistic signaling on pituitary somatotropes, resulting in amplified, pulsatile GH release compared to either compound alone.

Laboratory Handling, Reconstitution, and Storage Protocols

Maintaining reagent integrity requires strict adherence to laboratory storage and handling guidelines. Lyophilized CJC-1295 No DAC is stable at room temperature for short periods during transit, but should be stored at -20°C or -80°C upon receipt for long-term preservation. Repeated freeze-thaw cycles must be avoided to prevent peptide backbone cleavage and aggregation.

Reconstitution should be performed under a laminar flow hood using sterile, laboratory-grade solvents such as bacteriostatic water or sterile 0.9% sodium chloride solution. Solvent should be introduced slowly down the inner vial wall without aggressive vortexing. Once reconstituted, aqueous solutions should be aliquoted into sterile microcentrifuge tubes and maintained at 2°C to 8°C for short-term experiment schedules, or frozen at -80°C for extended research timelines. Detailed experimental protocols are documented across our research library hub.

Quality Assurance at PX1 Research: USA Manufacturing and Compliance

PX1 Research maintains stringent quality control protocols across all reagent manufacturing and distribution facilities. Derived from domestic, GMP-compliant facilities in California and Arizona, our research peptides are synthesized under controlled chemical conditions to minimize trifluoroacetic acid (TFA) residual salts and eliminate organic impurities.

Every production run undergoes complete lot-level verification. We publish transparent, downloadable HPLC and MS analytical reports for every lot, enabling laboratory staff to verify sequence integrity and purity before initiating preclinical studies. Institutional buyers managing large-scale screening projects can coordinate custom fulfillment and bulk tier options through our dedicated wholesale laboratory portal.